Logo image of MCRB

SERES THERAPEUTICS INC (MCRB) Stock Fundamental Analysis

USA - NASDAQ:MCRB - US81750R2013 - Common Stock

17.62 USD
-0.41 (-2.27%)
Last: 9/19/2025, 12:39:43 PM
Fundamental Rating

2

Taking everything into account, MCRB scores 2 out of 10 in our fundamental rating. MCRB was compared to 540 industry peers in the Biotechnology industry. While MCRB seems to be doing ok healthwise, there are quite some concerns on its profitability. MCRB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MCRB has reported negative net income.
In the past year MCRB has reported a negative cash flow from operations.
MCRB had negative earnings in 4 of the past 5 years.
In the past 5 years MCRB reported 4 times negative operating cash flow.
MCRB Yearly Net Income VS EBIT VS OCF VS FCFMCRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

With an excellent Return On Assets value of 0.10%, MCRB belongs to the best of the industry, outperforming 89.26% of the companies in the same industry.
With an excellent Return On Equity value of 0.99%, MCRB belongs to the best of the industry, outperforming 90.74% of the companies in the same industry.
Industry RankSector Rank
ROA 0.1%
ROE 0.99%
ROIC N/A
ROA(3y)-34.45%
ROA(5y)-29.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MCRB Yearly ROA, ROE, ROICMCRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MCRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MCRB Yearly Profit, Operating, Gross MarginsMCRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

MCRB has more shares outstanding than it did 1 year ago.
MCRB has more shares outstanding than it did 5 years ago.
MCRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MCRB Yearly Shares OutstandingMCRB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
MCRB Yearly Total Debt VS Total AssetsMCRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -12.03, we must say that MCRB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MCRB (-12.03) is worse than 75.74% of its industry peers.
There is no outstanding debt for MCRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.03
ROIC/WACCN/A
WACCN/A
MCRB Yearly LT Debt VS Equity VS FCFMCRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

MCRB has a Current Ratio of 0.94. This is a bad value and indicates that MCRB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.94, MCRB is doing worse than 87.96% of the companies in the same industry.
MCRB has a Quick Ratio of 0.94. This is a bad value and indicates that MCRB is not financially healthy enough and could expect problems in meeting its short term obligations.
MCRB has a worse Quick ratio (0.94) than 87.22% of its industry peers.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.94
MCRB Yearly Current Assets VS Current LiabilitesMCRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

MCRB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.16%, which is quite impressive.
EPS 1Y (TTM)37.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MCRB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.59% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y101.59%
EPS Next 2Y21.03%
EPS Next 3Y13.89%
EPS Next 5Y21.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MCRB Yearly Revenue VS EstimatesMCRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
MCRB Yearly EPS VS EstimatesMCRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MCRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MCRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MCRB Price Earnings VS Forward Price EarningsMCRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MCRB Per share dataMCRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as MCRB's earnings are expected to grow with 13.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.03%
EPS Next 3Y13.89%

More info and screens

0

5. Dividend

5.1 Amount

MCRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERES THERAPEUTICS INC

NASDAQ:MCRB (9/19/2025, 12:39:43 PM)

17.62

-0.41 (-2.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners35.47%
Inst Owner Change-96.28%
Ins Owners0.35%
Ins Owner Change0.18%
Market Cap154.18M
Analysts78
Price Target41.41 (135.02%)
Short Float %13.28%
Short Ratio5.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.81%
Min EPS beat(2)-51.81%
Max EPS beat(2)50.19%
EPS beat(4)3
Avg EPS beat(4)10.5%
Min EPS beat(4)-51.81%
Max EPS beat(4)50.19%
EPS beat(8)5
Avg EPS beat(8)8.86%
EPS beat(12)5
Avg EPS beat(12)2.11%
EPS beat(16)6
Avg EPS beat(16)12.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.47%
PT rev (3m)-55.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)118.02%
EPS NY rev (3m)107.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.19
P/tB 11.19
EV/EBITDA N/A
EPS(TTM)-14.83
EYN/A
EPS(NY)-10.38
Fwd EYN/A
FCF(TTM)-17.03
FCFYN/A
OCF(TTM)-16.98
OCFYN/A
SpS0
BVpS1.58
TBVpS1.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.1%
ROE 0.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.45%
ROA(5y)-29.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.95%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.94
Quick Ratio 0.94
Altman-Z -12.03
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)94.28%
Cap/Depr(5y)90.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.41%
EPS Next Y101.59%
EPS Next 2Y21.03%
EPS Next 3Y13.89%
EPS Next 5Y21.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.86%
EBIT Next 3Y9.36%
EBIT Next 5YN/A
FCF growth 1Y-18.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.63%
OCF growth 3YN/A
OCF growth 5YN/A